Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous versus homologous COVID-19 booster vaccination after primary Sinovac/Butantan series
RBR-9nn3scwPhase 4Not yet recruiting
- Sponsor
- Instituto D’Or de Pesquisa e Ensino
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 4, randomised trial of coronavac, ChAdOx1 nCoV-19, tozinameran and Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Instituto D’Or de Pesquisa e Ensino. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
coronavacChAdOx1 nCoV-19tozinameranAd26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-9nn3scw.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9nn3scw.